ARCUTIS BIOTHERAPEUTICS, INC. Paid-in-Kind Interest
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Paid-in-Kind Interest of $941.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. paid-in-kind interest for the quarter ending 2026-06-30 was $480.00K, a 11.37% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. paid-in-kind interest for the quarter ending 2026-03-31 was $461.00K, a 11.08% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. paid-in-kind interest for the quarter ending 2025-12-31 was $461.00K, a 82.24% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. paid-in-kind interest for the quarter ending 2025-09-30 was $449.00K, a 43.88% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. paid-in-kind interest for fiscal 2025 was $1.76M, a 67.51% decline from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. paid-in-kind interest for fiscal 2024 was $5.40M, a 34.09% increase from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. paid-in-kind interest for fiscal 2023 was $4.03M, a 54.64% increase from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. paid-in-kind interest for fiscal 2022 was $2.61M.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $480.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $941.00K 10-Q · filed 2026-08-05 | $1.40M derived: sum of 3 quarters · filed 2026-08-05 | $1.85M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $461.00K 10-Q · filed 2026-05-06 | $922.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.37M derived: sum of 3 quarters · filed 2026-05-06 | $1.80M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $461.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $910.00K derived: sum of 2 quarters · filed 2026-02-25 | $1.34M derived: sum of 3 quarters · filed 2026-08-05 | $1.76M 10-K · filed 2026-02-25 |
| 2025-09-30 | $449.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $880.00K derived: sum of 2 quarters · filed 2026-08-05 | $1.29M 10-Q · filed 2025-10-28 | $3.89M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $431.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $846.00K 10-Q · filed 2026-08-05 | $3.44M derived: sum of 3 quarters · filed 2026-08-05 | $4.24M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $415.00K 10-Q · filed 2026-05-06 | $3.01M derived: sum of 2 quarters · filed 2026-05-06 | $3.81M derived: sum of 3 quarters · filed 2026-05-06 | $4.82M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.40M derived: sum of 2 quarters · filed 2026-02-25 | $4.40M derived: sum of 3 quarters · filed 2026-02-25 | $5.40M 10-K · filed 2026-02-25 |
| 2024-09-30 | $800.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $1.80M derived: sum of 2 quarters · filed 2025-10-28 | $2.81M 10-Q · filed 2025-10-28 | $3.83M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $2.01M 10-Q · filed 2025-08-06 | $3.02M derived: sum of 3 quarters · filed 2026-02-25 | $4.04M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $1.00M 10-Q · filed 2025-05-06 | $2.02M derived: sum of 2 quarters · filed 2026-02-25 | $3.04M derived: sum of 3 quarters · filed 2026-02-25 | $4.04M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.03M derived: sum of 2 quarters · filed 2026-02-25 | $3.04M derived: sum of 3 quarters · filed 2026-02-25 | $4.03M 10-K · filed 2026-02-25 |
| 2023-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $2.02M derived: sum of 2 quarters · filed 2024-11-06 | $3.01M 10-Q · filed 2024-11-06 | $4.03M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $2.00M 10-Q · filed 2024-08-14 | $3.01M derived: sum of 3 quarters · filed 2025-02-25 | $3.82M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $994.00K 10-Q · filed 2024-05-14 | $2.01M derived: sum of 2 quarters · filed 2025-02-25 | $2.81M derived: sum of 3 quarters · filed 2025-02-25 | $3.21M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $1.82M derived: sum of 2 quarters · filed 2025-02-25 | $2.21M derived: sum of 3 quarters · filed 2025-02-25 | $2.61M 10-K · filed 2025-02-25 |
| 2022-09-30 | $802.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $1.20M derived: sum of 2 quarters · filed 2023-11-03 | $1.59M 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $396.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $788.00K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $392.00K 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |